Evidence map›Paper›PMID 36918770›Full record

ArticleBMC cardiovascular disorders2023

LncRNA HIF1A-AS2: a potential biomarker for early diagnosis of acute myocardial infarction and predictor of left ventricular dysfunction.

Eman Tayae, Eman Amr, Amr Zaki, Dalal Elkaffash

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cardiovascular disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. LncRNAs as Emerging Diagnostic Biomarkers for Cardiovascular Diseases: Evidence Synthesis Through Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Eman TayaeClinical Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. Eman.Tayae@alexmed.edu.eg.ORCID 0000-0003-3742-6438
Eman AmrClinical Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Amr ZakiCardiology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Dalal ElkaffashClinical Pathology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Alexandria University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRapid diagnosis of acute myocardial infarction (AMI) is the subject of many clinical studies as it enables an effective therapy, preventing adverse progression of AMI and increasing survival rates. Recent studies have revealed that specific blood-based long non-coding RNAs (lncRNAs) are deregulated in patients with AMI and serve as promising diagnostic and prognostic tools. The current study aimed to determine the potential role of a hypoxia-responsive lncRNA, hypoxia-inducible factor 1A antisense RNA 2 (HIF1A-AS2), as a biomarker for early diagnosis and predictor of left ventricular dysfunction (LVD).

methodsThis study was carried out on 48 patients with AMI and 50 age-and sex-matched controls. The relative quantification of HIF1A-AS2 expression was done using reverse transcription real-time polymerase chain reaction.

resultsCompared to the control group, HIF1A-AS2 were significantly higher in MI patients (P < 0.001). Interestingly, patients presenting within 3 h of chest pain onset had elevated levels of HIF1A-AS2 as compared to patients with late presentation. The ROC curve was constructed to assess HIF1A-AS2 as an early marker. It demonstrated higher sensitivity (94%) and specificity (86%). Moreover, the multivariate regression analysis revealed that HIF1A-AS2 was significantly associated with LVD in the patient group after 6 months follow up (p = 0.018).

conclusionOur study suggests that HIF1A-AS2 may be a potential early diagnostic biomarker of AMI with high sensitivity. In addition, it might have a promising role as a predictor of left ventricular dysfunction.

Indexed as

Myocardial InfarctionRNA, Long NoncodingVentricular Dysfunction, LeftBiomarkersEarly DiagnosisHumansHypoxiaHypoxia-Inducible Factor 1, alpha SubunitRNA, AntisenseBiomarkersHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitRNA, AntisenseRNA, Long NoncodingAntisense RNAEarly biomarkerHypoxia-inducible factor 1ALong non-coding RNAMyocardial infarction

Identifiers

PMID36918770
PMCPMC10012703
OpenAlexW4324149189

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read58
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.